CY1119829T1 - Βιοαποικοδομησιμες συνθεσεις απελευθερωσης φαρμακου - Google Patents

Βιοαποικοδομησιμες συνθεσεις απελευθερωσης φαρμακου

Info

Publication number
CY1119829T1
CY1119829T1 CY20171101219T CY171101219T CY1119829T1 CY 1119829 T1 CY1119829 T1 CY 1119829T1 CY 20171101219 T CY20171101219 T CY 20171101219T CY 171101219 T CY171101219 T CY 171101219T CY 1119829 T1 CY1119829 T1 CY 1119829T1
Authority
CY
Cyprus
Prior art keywords
biodegradable drug
drug release
release compositions
polyester
polyethylene glycol
Prior art date
Application number
CY20171101219T
Other languages
English (en)
Inventor
Georges Gaudriault
Original Assignee
Medincell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45809329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119829(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medincell filed Critical Medincell
Publication of CY1119829T1 publication Critical patent/CY1119829T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/08—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing solids as carriers or diluents
    • A01N25/10—Macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/66—Polyesters containing oxygen in the form of ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Dentistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Immunology (AREA)
  • Pest Control & Pesticides (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)

Abstract

Περιγράφονται βιοαποικοδομήσιμες συνθέσεις απελευθέρωσης φαρμάκου που περιλαμβάνουν ένα συμπολυμερές τριών συστάδων που περιέχει έναν πολυεστέρα και μια πολυαιθυλενογλυκόλη και ένα συμπολυμερές δύο συστάδων που περιέχει έναν πολυεστέρα και μια πολυαιθυλενογλυκόλη με τελική κάλυψη, καθώς και μια φαρμακευτικώς δραστική ουσία.
CY20171101219T 2010-12-29 2017-11-22 Βιοαποικοδομησιμες συνθεσεις απελευθερωσης φαρμακου CY1119829T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061428007P 2010-12-29 2010-12-29
PCT/IB2011/003323 WO2012090070A2 (en) 2010-12-29 2011-12-29 Biodegradable drug delivery compositions

Publications (1)

Publication Number Publication Date
CY1119829T1 true CY1119829T1 (el) 2018-06-27

Family

ID=45809329

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101219T CY1119829T1 (el) 2010-12-29 2017-11-22 Βιοαποικοδομησιμες συνθεσεις απελευθερωσης φαρμακου

Country Status (36)

Country Link
US (9) US9023897B2 (el)
EP (3) EP3586825B1 (el)
JP (2) JP6134269B2 (el)
KR (1) KR101741055B1 (el)
CN (1) CN103491946B (el)
AU (1) AU2011350898B2 (el)
BR (1) BR112013016662B1 (el)
CA (1) CA2822854C (el)
CL (1) CL2013001942A1 (el)
CO (1) CO6751290A2 (el)
CU (1) CU24203B1 (el)
CY (1) CY1119829T1 (el)
DK (1) DK2658525T3 (el)
EA (1) EA027046B1 (el)
ES (3) ES2733915T3 (el)
FI (1) FI3586825T3 (el)
HR (1) HRP20171810T1 (el)
HU (1) HUE037349T2 (el)
IL (1) IL227235A (el)
LT (1) LT2658525T (el)
MA (1) MA34832B1 (el)
ME (1) ME02915B (el)
MX (1) MX347090B (el)
MY (1) MY165655A (el)
NO (1) NO2658525T3 (el)
NZ (1) NZ612326A (el)
PL (3) PL3586825T3 (el)
PT (1) PT2658525T (el)
RS (1) RS56550B1 (el)
SG (2) SG191414A1 (el)
SI (1) SI2658525T1 (el)
SM (1) SMT201700550T1 (el)
TN (1) TN2013000267A1 (el)
UA (1) UA112069C2 (el)
WO (1) WO2012090070A2 (el)
ZA (1) ZA201304687B (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6134788B2 (ja) * 2012-06-27 2017-05-24 メドインセルル 疎水性組成物のための生分解性薬物送達
ES2875957T3 (es) 2012-12-20 2021-11-11 Amgen Inc Agonistas del receptor APJ y usos de los mismos
EP2896402A1 (en) 2014-01-20 2015-07-22 Vect-Horus Activated neurotensin molecules and the uses thereof
JP6640725B2 (ja) 2014-01-27 2020-02-05 セントレ ナショナル デ ラ レチャーチェ シャーティフィック ｓｐａｄｉｎのレトロ−インベルソ類似体は増大された抗うつ作用を示す
FR3027522B1 (fr) 2014-10-27 2016-12-09 I Ceram Composition poreuse chargee en principe actif
JP6739455B2 (ja) 2015-03-12 2020-08-12 クロス・バイオサイエンシズ・ベー・フェー 無水生体適合性複合材料
TWI798161B (zh) 2015-09-21 2023-04-11 瑞士商梯瓦製藥國際有限公司 持續釋放的奧氮平調配物
PL3377041T3 (pl) 2015-11-16 2024-03-11 Medincell S.A. Sposób morselizacji i/lub kierowania farmaceutycznie aktywnych składników do tkanki maziowej
EP4378535B1 (en) 2016-11-16 2026-02-25 Persica Pharmaceuticals Ltd. Antibiotic formulations for lower back pain
AU2018238136A1 (en) 2017-03-20 2019-11-07 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
EP3655038B1 (en) 2017-07-17 2024-12-18 Medincell S.A. Pharmaceutical composition
WO2019070950A1 (en) 2017-10-04 2019-04-11 Fashion Chemicals Gmbh & Co. Kg NOVEL POLYLACTIC ACID ESTERS AND COMPOSITIONS THEREOF
GB201900258D0 (en) * 2019-01-08 2019-02-27 Medincell Pharmaceutical composition
EP4706658A2 (en) 2019-09-13 2026-03-11 Medincell S.A. Drug delivery formulations
CN110638963A (zh) * 2019-11-01 2020-01-03 慧生医学科技(徐州)有限公司 一种可降解缓释药物组合物及制备方法
GB202010340D0 (en) 2020-07-06 2020-08-19 Medincell Pharmaceutical composition
US20240099964A1 (en) 2020-12-16 2024-03-28 Medincell S.A. Methods and Compositions for the Prophylactic Treatment of SARS-CoV-2 virus (COVID-19)
WO2022153262A1 (en) 2021-01-18 2022-07-21 Anton Frenkel Pharmaceutical dosage form
US20240148641A1 (en) 2021-03-17 2024-05-09 Medincell S.A. Long Acting Injectable Formulation Comprising Risperidone and Biodegradable Polymers
WO2022229402A1 (en) * 2021-04-30 2022-11-03 Medincell Sa New formulation
AU2022308198A1 (en) 2021-07-06 2024-02-01 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome
CN118159252A (zh) 2021-08-05 2024-06-07 美蒂森股份公司 药物组合物
EP4583845A4 (en) * 2022-09-08 2025-11-05 Univ Ramot STIMULUS-SENSITIVE PROGRAMMABLE POLYMER FORMULATIONS
DK4554562T3 (da) 2023-01-10 2025-12-01 Medincell Sa Olanzapinsammensætninger og fremgangsmåder til anvendelse deraf
WO2025104289A1 (en) 2023-11-17 2025-05-22 Medincell S.A. Antineoplastic combinations
WO2025224317A1 (en) * 2024-04-25 2025-10-30 Medincell S.A. A method for targeting pharmaceutically active principle in total knee replacement
WO2026013080A1 (en) 2024-07-08 2026-01-15 InnoCore Technologies Holding B.V. Pharmaceutical composition based on biodegradable polymers comprising polyoxazoline

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US5071643A (en) 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
EP0343850B1 (en) * 1988-05-23 1994-07-20 The Procter & Gamble Company Absorbent structures from mixed furnishes
US5632727A (en) 1988-10-03 1997-05-27 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5221534A (en) * 1989-04-26 1993-06-22 Pennzoil Products Company Health and beauty aid compositions
US5077049A (en) 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
USRE37950E1 (en) 1990-04-24 2002-12-31 Atrix Laboratories Biogradable in-situ forming implants and methods of producing the same
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
SG47445A1 (en) * 1993-11-19 1998-04-17 Janssen Pharmaceutica Nv Microencapsulated 3-piperidinyl-substituted1 1 2-benzisoxazoles and 1 2-benzisothiazoles
KR0148704B1 (ko) 1994-01-10 1998-08-17 김상응 생체분해성 약물전달용 고분자
CA2187353C (en) 1994-04-08 2007-05-22 Gerald L. Yewey Liquid delivery compositions
AU4652596A (en) 1995-01-09 1996-07-31 Atrix Laboratories, Inc. Liquid polymer delivery system
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
FR2741628B1 (fr) 1995-11-29 1998-02-06 Centre Nat Rech Scient Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
IL118235A0 (en) 1996-05-13 1996-09-12 Univ Ben Gurion Composition and method for forming biodegradable implants in situ and uses of these implants
US5711958A (en) * 1996-07-11 1998-01-27 Life Medical Sciences, Inc. Methods for reducing or eliminating post-surgical adhesion formation
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6261583B1 (en) 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
KR100416242B1 (ko) 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법
KR100446101B1 (ko) 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
US6592899B2 (en) * 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
AU2003222310B2 (en) * 2002-05-03 2009-04-09 Janssen Pharmaceutica N.V. Polymeric microemulsions
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
US7160551B2 (en) 2002-07-09 2007-01-09 The Board Of Trustees Of The University Of Illinois Injectable system for controlled drug delivery
US20050112170A1 (en) * 2003-11-20 2005-05-26 Hossainy Syed F. Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same
US7262253B2 (en) * 2003-12-02 2007-08-28 Labopharm, Inc. Process for the preparation of amphiphilic poly (N-vinyl-2-pyrrolidone) block copolymers
US20060034889A1 (en) * 2004-08-16 2006-02-16 Macromed, Inc. Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof
CA2609268A1 (en) * 2005-05-23 2006-11-30 University Of Utah Research Foundation Echogenic microbubbles and microemulsions for ultrasound-enhanced nanoparticle-mediated delivery of agents
EP3058972A1 (en) * 2005-11-17 2016-08-24 Zogenix, Inc. Delivery of viscous formulations by needle-free injection
AR064286A1 (es) * 2006-12-13 2009-03-25 Quiceno Gomez Alexandra Lorena Produccion de dispositivos oftalmicos basados en la polimerizacion por crecimiento escalonado fotoinducida
US20090004243A1 (en) 2007-06-29 2009-01-01 Pacetti Stephen D Biodegradable triblock copolymers for implantable devices
WO2009060473A2 (en) 2007-11-06 2009-05-14 Panacea Biotec Limited Injectable compositions, processes and uses thereof
JP2010215562A (ja) 2009-03-17 2010-09-30 Kansai Univ 膨隆剤組成物および膨隆剤製造方法

Also Published As

Publication number Publication date
PL3257498T3 (pl) 2020-02-28
EP3257498A1 (en) 2017-12-20
HRP20171810T1 (hr) 2017-12-29
US20190099495A1 (en) 2019-04-04
WO2012090070A2 (en) 2012-07-05
EP3257498B1 (en) 2019-04-24
US20160030581A1 (en) 2016-02-04
EP2658525A2 (en) 2013-11-06
MA34832B1 (fr) 2014-01-02
EA027046B1 (ru) 2017-06-30
SG10201508568VA (en) 2015-11-27
EP3586825A1 (en) 2020-01-01
ES2733915T3 (es) 2019-12-03
CA2822854C (en) 2020-01-07
JP2014502613A (ja) 2014-02-03
KR101741055B1 (ko) 2017-05-29
FI3586825T3 (fi) 2023-03-20
UA112069C2 (uk) 2016-07-25
ME02915B (me) 2018-04-20
CU20130091A7 (es) 2013-08-29
AU2011350898A1 (en) 2013-07-11
SI2658525T1 (en) 2018-04-30
WO2012090070A3 (en) 2012-11-01
SMT201700550T1 (it) 2018-01-11
DK2658525T3 (da) 2017-11-13
US9023897B2 (en) 2015-05-05
KR20130135294A (ko) 2013-12-10
EP2658525B1 (en) 2017-08-30
JP2017039758A (ja) 2017-02-23
RS56550B1 (sr) 2018-02-28
CN103491946B (zh) 2016-08-10
US20220202942A1 (en) 2022-06-30
US20190192665A1 (en) 2019-06-27
PT2658525T (pt) 2017-11-30
JP6302983B2 (ja) 2018-03-28
ZA201304687B (en) 2014-03-26
TN2013000267A1 (en) 2014-11-10
US20150157727A1 (en) 2015-06-11
JP6134269B2 (ja) 2017-05-24
MX347090B (es) 2017-04-11
CU24203B1 (es) 2016-09-30
IL227235A (en) 2016-05-31
PL2658525T3 (pl) 2018-02-28
US20120172454A1 (en) 2012-07-05
ES2647614T3 (es) 2017-12-22
ES2939744T3 (es) 2023-04-26
BR112013016662A2 (pt) 2016-10-04
NO2658525T3 (el) 2018-01-27
PL3586825T3 (pl) 2023-04-11
WO2012090070A8 (en) 2013-08-08
US20210154301A1 (en) 2021-05-27
LT2658525T (lt) 2017-12-11
US20230091533A1 (en) 2023-03-23
AU2011350898B2 (en) 2016-09-08
CN103491946A (zh) 2014-01-01
CL2013001942A1 (es) 2014-07-04
MX2013007682A (es) 2013-10-30
SG191414A1 (en) 2013-08-30
EA201390783A1 (ru) 2013-12-30
BR112013016662B1 (pt) 2021-08-03
MY165655A (en) 2018-04-18
NZ612326A (en) 2014-10-31
US20210038724A1 (en) 2021-02-11
CA2822854A1 (en) 2012-07-05
CO6751290A2 (es) 2013-09-16
HUE037349T2 (hu) 2018-08-28
EP3586825B1 (en) 2023-01-18

Similar Documents

Publication Publication Date Title
CY1119829T1 (el) Βιοαποικοδομησιμες συνθεσεις απελευθερωσης φαρμακου
BR112014031773A2 (pt) entrega de drogas biodegradável para composições hidrofóbicas
EA201400172A1 (ru) Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
EP2544701A4 (en) POLYMER CONJUGATES FOR DRUG DELIVERY AND METHOD FOR THE PRODUCTION AND USE THEREOF
MX347056B (es) Composiciones farmaceuticas.
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
MX356111B (es) Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata.
TR200904159A1 (tr) Değiştirilmiş salım sağlayan emoksipin formülasyonları.
EP4374861A3 (en) A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
EA200900958A1 (ru) Препарат невирапина пролонгированного высвобождения
UY31887A (es) Uso de dronedarona para la preparación de un medicamento para uso en la prevención de la cardioversión
PH12013500882A1 (en) Pharmaceutical compositions
TR201803451T4 (tr) Olmesartan formülasyonlari.
GEP20115158B (en) Use of ivabradine for obtaining medicaments intended for the treatment of endothelial dysfunction
EA200901387A1 (ru) Фармацевтическая композиция, включающая дезлоратадин
WO2013177147A3 (en) Copolymer-xerogel nanocomposites useful for drug delivery
TN2011000352A1 (en) New combination of active ingredients containing a non steroidal anti inflammatory drug and a colchicoside derivative
TH151376A (th) องค์ประกอบลำเลียงยาที่ย่อยสลายได้ทางชีวภาพ
WO2011083112A3 (en) Solid oral dosage form containing olmesartan medoxomil
TR201005911A2 (tr) Geliştirilmiş dissolüsyon profiline sahip bir ilaç formülasyonu.
TR201108071A2 (tr) Değiştirilmiş salım sağlayan emoksipin formülasyonları.
TR201108075A2 (tr) Değiştirilmiş salım sağlayan emoksipin formülasyonları.
TR201008517A2 (tr) Olmesartan medoksomil içeren ilaç formülasyonu.